What Vilate Treats: Main Uses and Benefits

Vilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) is used for managing conditions associated with bleeding. The therapeutic domain is applied across areas where additional symptomatic support is needed. Vilate is commonly used for Von Willebrand Disease (VWD) and Hemophilia A to provide supportive management in clinical settings. The medicine is relevant when symptoms that interfere with daily functioning require therapeutic intervention.

---

Clinical Contexts of Use

Vilate is applied in addressing symptom clusters that may become intense or disruptive, such as active bleeding. It is commonly used in situations involving recurrent or episodic manifestations to support managing symptoms associated with episodic manifestations, and is considered relevant for patients requiring supportive care for surgical procedures. This use may help ease the overall symptom burden and supports patients during episodes of heightened discomfort.

“This use may assist with functional stability and contribute to improved comfort during symptomatic periods.”

Quick Fact: Relevant for Symptoms related to Physical Discomfort

Vilate is used for managing conditions associated with bleeding, including situations involving recurrent manifestations, conditions presenting with acute episodes, and contexts involving heightened systemic burden.

Eligibility for Vilate (von Willebrand Factor/Coagulation Factor VIII Complex)

The official eligibility criteria for using Vilate are defined by specific patient populations and conditions documented in regulatory labeling.

Population Status	Regulatory Rule
Absolute Contraindication	The medicine is contraindicated in patients with a known history of severe hypersensitivity reactions, including anaphylaxis, to any ingredient in the formulation or to human plasma-derived products.
Age Restriction	Use for routine prophylaxis to reduce the frequency of bleeding episodes in Von Willebrand Disease (VWD) is not established in children under 6 years of age.
Established Use	Vilate is indicated for use in adults and adolescents with Hemophilia A, and in adults and children 6 years and older with VWD.

---

Condition-Based Eligibility

Continued use in patients with VWD carries a regulatory requirement for caution. Patients at risk for thromboembolic events must be closely monitored, as continued treatment may cause an excessive rise in Factor VIII activity, which may increase this risk.

For Pregnancy and Lactation, official regulatory documents indicate that safety has not been established in controlled human studies, and it is unknown if the product components are excreted into human milk.

Interactions with other medicines and products

Vilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) is a plasma-derived biological medicine whose official interaction profile is characterized by administrative restrictions rather than systemic drug-drug interactions.

Systemic Drug-Drug Interactions

Official regulatory labeling for this medicine explicitly states that no drug interactions are known with respect to metabolic or systemic effects. This means that interactions affecting the clearance or plasma exposure of the product via major pathways, such as those mediated by CYP enzymes or drug transporters, are not formally documented. Consequently, no specific medicinal products are listed as causing exposure-altering effects (e.g., changes in AUC or Cmax) when co-administered.

Mandatory Administration Restrictions

A critical restriction, classified as a physical administration incompatibility, is documented in official prescribing information. Vilate must not be mixed with any other medicinal products, nor should it be administered simultaneously through the same intravenous line or infusion set. This mandatory separation is required to prevent the potential for chemical or physical alteration of the complex, which could reduce the activity of the coagulation factors.

Food, Alcohol, and Supplements

Regulatory documents do not contain specific interaction statements regarding the co-use of Vilate with food, alcohol, herbal products, or dietary supplements.

️ How Vilate Works

Vilate is a plasma-derived combination biological product that works solely by providing two essential coagulation factors, Factor VIII (FVIII) and von Willebrand Factor (VWF), thereby influencing the two principal phases of the body's natural blood clotting process (hemostasis). This mechanism acts directly on both the primary and secondary stages of coagulation.

---

Influencing Fibrin Clot Formation (Secondary Hemostasis)

This domain covers the role of Factor VIII, which acts as a crucial cofactor for Factor IXa in the intrinsic coagulation cascade. Upon infusion and activation, FVIII accelerates the downstream generation of thrombin, ensuring the production of a fibrin clot, which reinforces the initial platelet plug. This action increases the rate of fibrin production, correcting the kinetic deficit in the propagation phase of the coagulation cascade.

---

Dual Action: Platelet Adhesion and Factor Stabilization

This domain focuses on the two mechanistic functions of von Willebrand Factor. First, VWF acts as an adhesive bridge to link platelets to the damaged vessel wall, immediately providing the adhesive component required for the initiation of primary hemostasis (platelet plug formation). Second, VWF binds tightly to FVIII, acting as a protective carrier protein that prevents the FVIII from being rapidly destroyed by natural proteases, extending its functional activity in the circulation.

---

The combined, synergistic action of VWF influencing platelet adhesion and FVIII contributing to the fibrin structure simultaneously influences the two principal phases of the coagulation process, resulting in the reconstitution of hemostatic function.

Vilate is administered exclusively by intravenous injection or infusion after reconstitution from its lyophilized powder form. The instructions for its use are specific to the clinical context and must be followed precisely.

---

Administration and Dosing

Vilate dosage is highly individualized, calculated based on the patient's body weight and the required increase in factor activity (IU/kg).

Context	Typical Labeled Dose (VWF:RCo or FVIII)	Frequency and Duration
Routine Prophylaxis	20 to 40 IU/kg of the deficient factor	Two or three times per week (long-term regimen)
Acute Bleeding	Initial dose 20 to 60 IU/kg VWF:RCo	Repeated every 12 to 24 hours; continued until clinical resolution (e.g., at least 1 day for minor bleeds)
Perioperative Management	Initial dose 40 to 60 IU/kg VWF:RCo	Continued every 12 to 24 hours for up to 6 days or more post-major surgery

---

Preparation and Use Requirements

As a powder, Vilate requires reconstitution before injection. The procedure mandates that the powder and diluent must reach room temperature before mixing, which should be done by gentle swirling—not shaking. The solution must be used promptly, within the specified timeframe following reconstitution. The intravenous infusion should be administered slowly, typically at a rate of 2 to 4 mL per minute.

For use in pediatric patients, routine prophylaxis is indicated for children 6 years of age and older. The solution is for single use only and must not be mixed with other medicinal products in the same infusion line.

Research Evidence / Overview of Studies for Vilate

Vilate was studied for conditions associated with bleeding, according to research documents. The research effort includes prospective (planned) multi-center studies that research examined how patients responded to the medicine during acute bleeding episodes and over defined observation periods. This overview summarizes the structure of this evidence, outlining what has been studied and what research gaps exist.

---

Evidence for Use in Von Willebrand Disease (VWD)

The evidence for VWD, a condition characterized by fluctuating or episodic manifestations, comes from planned international clinical trials and post-marketing observational studies. Researchers studies monitored the presence of the medicine in adults, adolescents, and children with different types of VWD, including severe forms. These studies focused on outcomes related to physical discomfort during acute events.

Study Endpoints and Measures in VWD Trials

To assess the performance of the medicine, the studies focused on specific measures. For the management of acute bleeds, researchers assessed the hemostatic efficacy—referring to the measurement of hemostatic control—using a global rating scale based on the investigator's judgment. For potential bleed prevention (prophylaxis), the key measure was studied for the Annualized Bleeding Rate (ABR), which tracks the average number of bleeding episodes a patient experiences in a year. Studies also research examined how the levels of von Willebrand Factor (VWF) and Factor VIII (FVIII) recovered in the blood following administration, providing data about temporary physiological imbalance.

---

Evidence for Use in Hemophilia A

Research for Hemophilia A focused on patients with severe disease who have been treated previously. The evidence consists mainly of pooled data from multiple short-term studies and specific cohort research. Vilate was evaluated in research exploring its short-term symptom patterns in patients dealing with acute, disruptive episodes of bleeding.

Immune Tolerance Induction (ITI) Research

A specific research area was studied for patients with Hemophilia A who have developed inhibitors. These trials, often smaller, open-label, and observational in design, research describes the use of the medicine as part of an Immune Tolerance Induction (ITI) protocol. The main goal of this research examined the change in the level of the inhibitors in the blood and tracking the change in the FVIII pharmacokinetic measurements.

---

Gaps in Evidence and Areas of Uncertainty

The research provides context about how the medicine was evaluated in clinical settings, but limitations exist that are common across many treatments for rare bleeding disorders:

• Comparative Evidence: Comparative evidence is lacking from large-scale randomized trials comparing this specific plasma-derived FVIII/VWF product directly to other factor replacement therapies.
• Long-term Safety: While the immediate and intermediate outcomes are documented, long-term effects are not fully established, particularly concerning the outcomes of continued use for many years, as follow-up durations were defined and limited in the initial registration trials.

Key Studies & References

1. VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) - DailyMed (Official FDA Prescribing Information)
2. Clinical study to assess how well wilate works in the regular treatment of young children with severe von Willebrand disease (WIL-33) - ISRCTN Registry (ISRCTN11217735)
3. Immune tolerance induction using wilate, a human von Willebrand factor/factor VIII complex, in patients with severe haemophilia A and inhibitors: A retrospective study of 11 children (Retrospective ITI Study)
4. The von Willebrand factor in pregnancy (VIP) study: A prospective, multicenter, investigator-initiated study (mentioned in clinical trial registries)

Common questions about Vilate (FAQ)

Q: How long do most people stay on Vilate?

The length of treatment with Vilate is determined by the specific reason for its use. For routine bleed prevention (prophylaxis), official documents describe the medicine as a long-term regimen. When treating an acute bleeding episode, the medicine is continued until the bleeding has clinically resolved, which may be at least one day for minor bleeds.

---

Q: Can Vilate still be effective if I take it with other daily medications?

Official product labeling indicates that no systemic drug interactions are formally known, meaning the effectiveness of Vilate is generally not affected by other systemic medicines. However, the regulatory restriction states that Vilate must not be mixed with any other products or administered through the same intravenous line.

---

Q: Is Vilate known to cause any long-term health concerns?

Official information describes a theoretical risk of transmitting infectious agents, due to its plasma origin, although the product undergoes rigorous cleaning processes. Long-term use may also lead to the development of neutralizing antibodies, called inhibitors, which can reduce the effectiveness of the treatment over time.

---

Q: Do I need to get blood tests done regularly while I am taking Vilate?

Regulatory documents state the importance of close monitoring during treatment. Blood tests are required to check the levels of von Willebrand Factor (VWF) and Factor VIII activity in the blood. This monitoring is necessary to ensure the factor levels do not become excessively high, especially for patients with pre-existing cardiovascular risk factors, and to track for the development of inhibitors.

---

Q: Does the medicine Vilate make you feel tired or dizzy?

Dizziness is documented in the product information as a common adverse reaction. While tiredness or fatigue is sometimes listed in patient resources as an associated symptom, official adverse reaction lists specifically identify dizziness as a common side effect.

---

Q: Is there a weight limit or minimum for taking Vilate?

The dosage of Vilate is highly individualized and is calculated based on the patient's body weight (IU/kg) to achieve the required factor activity in the blood. Official regulatory labeling uses this weight-based calculation but does not define a specific minimum or maximum weight limit as an eligibility restriction or contraindication.

---

Q: Why do official documents say Vilate is for a specific age range?

The use of Vilate for routine prophylaxis (prevention of bleeding) in Von Willebrand Disease (VWD) is specifically indicated for children aged six years and older. This age range reflects the population that was included and studied in the initial clinical trials that supported the product's official approval.

---

Q: How does Vilate fit into the overall treatment plan for the condition it treats?

Vilate is a replacement therapy that provides essential blood clotting factors. Its role in treatment is indicated for three main purposes: on-demand treatment of active bleeding, management before and after surgery (perioperative), and routine prophylaxis (preventive treatment).

---

Q: What if I have a bad reaction to Vilate—what is considered an emergency?

Official information describes severe hypersensitivity reactions (anaphylaxis) by focusing on symptoms that require attention. These symptoms include swelling of the face or throat (angioedema), difficulty breathing or wheezing, tightness in the chest, and severe drop in blood pressure.

---

Q: What is the research evidence summary for using Vilate in children?

The medicine was studied and is indicated for use in children aged six years and older who have Von Willebrand Disease (VWD). Official studies examined the use of Vilate for both routine prophylaxis (preventive treatment) and for treating active bleeding episodes in this specific age group.

---

Q: What is Vilate used for, besides the main condition?

The official regulatory indications for Vilate list two main conditions: Von Willebrand Disease (VWD) and Hemophilia A. The medicine is formally approved for use only for patients with these specific inherited blood clotting factor deficiencies.

---

Q: How quickly does Vilate usually start working?

While the onset of action is not explicitly described, studies indicate that the medicine's activity is tracked by measuring the factor levels in the blood. Peak concentration is typically assessed about 30 minutes following the completion of the infusion.

---

Q: Can Vilate be used by elderly people?

The official clinical studies included patients aged 65 and older who had Von Willebrand Disease (VWD). Regulatory reviews indicate that no overall differences in safety or effectiveness were observed between elderly subjects and younger subjects in the clinical studies.

---

Q: Are there any restrictions on driving while using Vilate?

Official product documents include information that caution is warranted when driving or operating machinery. This is noted because dizziness is a commonly reported adverse reaction, and any instance of dizziness may potentially impair awareness.

---

Q: Can Vilate interact with things like alcohol or caffeine?

Official regulatory documents do not contain specific interaction statements regarding the co-use of Vilate with common substances such as alcohol or caffeine. This statement indicates that no specific interaction restrictions for these substances are documented in the product labeling.

---

Q: Can people with high blood pressure use Vilate?

Patients with pre-existing cardiovascular risk factors are noted in regulatory documents as having an increased risk of thromboembolic events (blood clots). Official guidelines state that these patients must be closely monitored during treatment.

---

Q: What are common user complaints about Vilate that aren't serious side effects?

Common adverse reactions documented in official information include pyrexia (fever), nausea, dizziness, and urticaria (hives). These reactions are documented based on their observed frequency in clinical data.

---

Q: What level of evidence supports the use of Vilate for its main indication?

The effectiveness of Vilate for its approved indications is supported by data from prospective, multi-center clinical trials. These studies examined the medicine in adults and children with both Von Willebrand Disease and Hemophilia A and form the basis of the regulatory approval.

---

Q: Is Vilate the final medicine used, or is it a starting point for treatment?

The medicine is noted for its variety of roles, which include on-demand treatment of active bleeding, surgical management, and long-term prophylaxis (preventive treatment). The specific application is determined by the patient’s clinical need.

---

Q: What happens if a dose of Vilate is missed?

For patients on a preventive (prophylactic) regimen, regulatory protocol states that a missed dose should be taken as soon as possible. The protocol states that treatment should then continue according to the regular schedule, and the next dose must not be doubled.

How to Store and Dispose of Wilate

Official labeling defines specific conditions for the storage and disposal of Wilate to maintain product stability.

Storage Requirements

• Primary Temperature: The unopened product must be stored in its original container in a refrigerator between 2 C and 8 C (36 F and 46 F). The product must not be frozen.
• Room Temperature: A single move to room temperature (up to 25 C) is allowed for up to six months, provided the date is recorded, but the product must not be returned to refrigeration.
• Post-Reconstitution: Once the powder is mixed, the solution must be administered immediately or within a maximum of three to four hours; it must not be mixed with other medicinal products.
• Child Safety: The medicine must be kept out of the reach and sight of children.

Disposal

Unused or expired Wilate and all associated materials (e.g., needles and syringes) must be disposed of according to local pharmaceutical waste requirements.

• Sharps: Used needles and syringes must be placed in a designated, puncture-proof sharps container.
• Restriction: The product should not be disposed of in household waste or poured down a sink or drain.